reason report
take-away men medicin men bu
bottom line convict op
strategi creat new front door healthcar success
diplomat dplo op remain well posit
specialty-focus mid-market pbm follow men
 medicin men bu tour earlier week featur
discuss two medacorp pbm specialist trip includ
site visit op lower
estim slightli given continu pharmedium headwind
remain consensu encourag manag
comment stabil gener deflat new potenti win
tour also met manag servic
op highlight on-going migrat valu base
care continu albeit slow pace continu believ hcit stock
focus shift value-bas care remain attract
hcit coverag like premier inc op posit
pharmedium becom tailwind met
jame cleari head ir bennett murphi visit
week come away meet confid core
busi perform well like long-term growth driver
concern continu pharmedium headwind
product memphi facil pharmedium volum
take time recov divis becom tailwind
reduc forward ep estim slightli remain
core busi perform well gener deflat
stabil manag also highlight gener deflat trend
appear stabil core busi perform well despit
headwind pharmedium lash absent unforeseen
headwind busi would perform high end adj
ebit growth guidanc renew major client
contract esrx mp fine next year
relationship mp remain strong current servic
pbm believ good chanc win
retail stand-alon busi also believ merger
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
posit view vertic merger tour includ panel two
pharmaci specialist signific experi build pbm
kol explain pbm sell season much competit
price year industri consolid led larger deal
volum stake pbm compet volum rate
lower prior year specialist indic
believ rebat simpli go away though could shift
point-of-car rebat expect brand price increas
rang twice per year averag annual increas
specialist also agre pillpack expens may difficult
sell direct manag care plan
comment express script gener posit view
express script esrx mp price aggress
enabl creat high retent rate good claim growth
howev aggress price may creat headwind margin
one kol indic op contract could see
rate improv given deal old
price market assum drug spend
improv price would lead increment save
well ebitda gener
esrx esrx may face margin headwind
specialist agre ci op far better own
script margin ci pbm like expand synergi
avail within specialti high drug-spend rang
reduc ep due price headwind
still posit specialist agre op
abl deliv effect front door healthcar
lower cost urgent care center doc offic er believ
move drug spend medic pharmaci abl
improv trend significantli also posit surpris hear
specialist state may get slightli less
aggress desir sell narrow network deal may
lead relief retail reimburs pressur manag
continu posit creat new front-door healthcar
believ aet mp transact enabl grow
pbm retail volum
dplo still grow pbm specialist call indic
seen dplo op compet middl market pbm deal
ldi np still grow refin claim platform
go-to-market strategi given mega-merg go
believ dplo may pick share given potenti disrupt
furthermor despit price pressur expect dplo pbm
post good gross margin
meet manag underscor migrat valu
continu slow pace consist recent popul
health puls call link meet manag highlight
support shift valu commerci side
migrat continu pace remain slow perhap due
posit low-cost effici provid care describ
littl pressur take risk payer explain qualiti
focu discuss insur earli
stage howev posit inevit shift valu
acquir insur underwrit experi help prepar
compani assum risk deploy mp
revenu cycl solut near-term
takeaway annual middl men medicin men
earlier week held annual men medicin men bu tour includ
site visit meet manag moder discuss two
pbm specialist part medacorp network site visit particularli
well attend rivet discuss ceo steve colli depart cfo tim
guttman new cfo jame cleari kol panel provid mani import insight
pbm sell season detail kol view pend vertic merger
favor believ substanti save gener integr medic
pharmaci benefit site visit highlight shift
valu remain steadi slow move overal come away trip reiter
posit view cvs-aet ci-esrx merger healthcar compani well
posit continu shift valu base care remain op lower
estim compani navig continu headwind pharmedium lash
visit abc headquart investor met ceo steve colli depart
cfo tim guttman in-com cfo jame cleari convers ceo steve colli
support sector say surpris littl confid sector
current level believ still good time repurchas share follow
discuss slightli cautiou pharmedium encourag abc
core busi sound like well impact takeaway discuss
follow
current servic rad pbm expect bid aggress stand-
manag indic feel compel need merg larg
suppli chain entiti like plan combin someon like walgreen could make
far sens given potenti long-term synergi
gener price trend appear moder brand price expect eventu
re-acceler mp state brand price increas
would unfavor ep impact result suspect face similar
core busi sound like perform well without pharmedium lash
headwind adj oper incom would like high-end prior
pharmedium lash headwind expect continu howev pharmedium
memphi facil soon begin ship commerci expect becom tailwind
abc custom base remain strong major re-contract effort
complet esrx contract fine chang control five-year contract
recent renew
anim health busi remain robust growth driver compani new cfo
jame cleari sound excit opportun sound commit return capit
long-term driver includ bio-similar in-sel opportun manufactur specialti
growth custom base inflat howev manag commit
ep growth annual basi
price increas expect januari gener deflat trend seen
level price increas expect januari despit challeng polit
environ though manag will put number brand price
increas continu believ manufactur take price increas
januari manufactur publicli state take price increas year
believ even heighten scrutini level appropri price
increas make sens market manufactur manag explain
need manufactur take increas drive valu small portion
contract fee servic arrang guid brand inflat
explain would ok price increas contract
dollar tie inflat even though abc revenu fee-for-servic
estim much fee still percent list price rate list price inflat slow
view headwind entir suppli chain
gener deflat improv slightli long-term guid unlik near-term amid question
price trend manag explain gener deflat prevail
econom issu busi improv deflat trend would impact
encourag hear manag believ data show stabil trend
believ consist analysi nadac data center medicar
medicaid servic analysi reli equal-weight data believ
discern stabil trend consist manag comment bode
well group support stabil trend accord manag
on-going work gener manufactur like teva ration product line take
product market price driven low
trend show gener deflat rang data sell-sid isnt
perfect exclud signific number discount factor buy-sid
manag guid deflat believ still trend
rang long-term normal rang would manag explain
get past gener stabil would like better place give long-term
view would like occur analyst day
gener deflat trend appear support manag comment stabil
gener launch lucr past fda approv drug
actual launch fda work approv drug effort combat
rise price howev manag explain drug approv
ultim launch well brand drug lose exclus loe mani gener
launch becom less lucr past accord manag
somewhat discourag data iqvia institut show much drug
face loe next five year gener launch may less lucr
past believ may still attract distributor manag describ
gener launch provid fair bit incom
rebat chang without chang wac sound unlik consist kol panel
manag explain believ chang rebat happen alon
overnight base discuss enact meaning chang lower drug cost
consum must chang wac lower overal drug price price
lower cash pay custom given size complex industri sound unlik
chang would enact overnight manag explain
possibl legisl would enact forc meaning chang would take
shift part part make sens therapeut area
manag explain greater market share part part due strength
relationship physician manag express strong support keep
certain therapeut class physician administr point oncolog exampl
howev manag explain model chang follow rule
contradict kol panel recap describ believ
drug purchas part benefit direct manufactur result would
like receiv benefit kol expect possibl
interest support physician interest own like
discuss potenti shift part part manag ask whether
would interest purchas specialti practic like ownership oncolog
group manag explain dont love prefer work support provid
rather work manag explain invest physician
dont think need make direct invest
invest strong complianc program internet pharmaci prior opioid crisi
field question on-going opioid crisi manag describ
implement robust complianc program began ship internet
pharmaci manag explain provid compani advanc program
mani competitor express confid reli longitudin
data bit player suppli chain report necessari data
daili basi view appear drop ball entiti
market-wid longitudin data ship pattern continu believ opioid repres
manag risk distributor link
discuss rise cfo jame cleari highlight robust anim health market
continu growth commerci servic
new cfo jame cleari doesnt sound like want rock boat site visit
opportun speak new cfo jame cleari formerli serv ceo
mwi veterinari suppli recent presid global commerci servic
anim mr cleari explain believ depart cfo tim guttman
great team place high degre confid peopl report
express confid abc core busi excit compani growth prospect
spoke strong custom base strength specialti franchis
explain expect new cfo role process remain
focu capit deploy organ growth strateg opportunist share
repurchas maintain dividend ask mr cleari explain took
role seem like big challeng fun opportun overal
encourag posit tone mr cleari believ experi mwi lead
anim health commerci servic busi help compliment ceo steve
lash remain headwind becom tailwind given mr
cleari experi run commerci servic busi discuss
headwind face lash consult busi lash process convert new
platform fusion cloud base system effici cost effect
fulli implement migrat three signific manufactur onto fusion far
expect move six year manag caution take time get
program onto new platform throughout compani still
convert program result lash expect remain headwind
manag guid lash becom real tailwind
disappoint hear lash continu weigh result long-term
program migrat sound like lash may becom tailwind
anim market sound robust jame cleari transit away directli lead
anim health busi encourag descript great market
expect remain strong long-term good growth prospect companion anim market
continu grow faster product anim margin somewhat impact
consolid manufactur remain low-cost oper great salesforc
custom relationship believ anim health remain good busi compel
guidanc impact pharmedium busi sound healthi hd smith
hd smith integr progress well heavi lift anticip dc
migrat manag explain pleas on-going integr hd smith
lost major custom process integr back offic
function current though manag yet publicli comment close hd
smith distribut center dc believ manag plan close hd smith
distribut center migrat abc newer well-autom facil anticip
dc re-purpos believ like want captur mani
synergi possibl reli modern effici dc network migrat like
occur describ want make sure custom impact
roll chang dc manag expect take opex realiz
full benefit encourag smooth integr thu far optimist
leverag abc effici dc network compani abl captur impact
synergi valu
without unexpect impact pharmedium would achiev
oper profit growth goal manag field sever question oper profit
growth guidanc meet initi guidanc adj oper profit
growth first rais cut twice current level flat y/i meanwhil adj opex growth
assumpt rais origin current manag
explain op-ex growth assumpt high origin guidanc anticip
opex growth go forward expect achiev greater effici dc
given technolog invest manag also explain without
unexpect pharmedium woe would upper end adj oper
incom guidanc provid follow hd smith transact view sound like core
busi perform in-lin ahead manag expect
encourag despit continu pharmedium woe
manag cut guidanc pharmedium woe weigh
pharmedium expect headwind tailwind thereaft manag
explain despit challeng face pharmedium feel good progress
made expect fda come anoth inspect
memphi facil near-term open dialogu fda month
hire independ auditor inspect facil provid list task
recommend complet process complet current
pharmedium expect remain headwind signific oper issu
manag work remedi remain item independ auditor
found still need attent current pharmedium three pharmaci ship product
memphi facil scalabl facil handl busi
sku end septemb memphi facil expect return
win back custom pharmedium may challeng concern
may face difficulti win back custom lost pharmedium period challeng
conced pharmedium busi lost lost in-sourc compound
health system believ busi well posit win back custom howev
explain certain quickli custom come back unit cost
low discount attract custom may like pharmedium advantag
facil highli autom allow substanti scale channel check
learn typic insourc compound much attract financi seen
oper challeng insourc compound materi tend lower shelf live
compound facil like pharmedium howev sinc shift made
sure incent former custom return pharmedium despit
concern manag continu expect pharmedium becom tailwind
long-term mid-teen ep growth target aspir manag guid adj ep
impli growth midpoint histor guid
long-term adj ep growth goal investor question given unusu
headwind face compani recent manag explain continu deliv
strong ep growth due part tax reform former target explain
aspir doesnt factor recent price trend manag explain
achiev rate everi year would difficult commit make manag also
explain improv gener deflat adj ep growth teen becom
investor seek driver sustain profit growth given flat adj oper incom growth
assumpt investor question manag catalyst better-sustain profit
growth manag explain believ biosimilar impact industri
anim health remain robust grow busi compani posit
continu growth due growth strong custom base addit manag
explain look addit area growth includ thing around data practic
manag oncolog want acquir practic express
desir explor practic explain work
lash complet abl explor avenu includ pursu
activ manag explain alway mani potenti deal
opportun said manag believ earn biggest roi organ growth
opportun add addit servic may compel futur
abc custom retent sound encourag deal could card
futur
major custom renew left alreadi renew contract
diplomat pharmaci express script describ great shape face
major renew though smaller gpo health system sound
though success renew major contract manag
word top pretti much lock encourag commentari
competitor disclos much book may bid remain
potenti share win follow sale store given rad opportun join
wbad purchas group fact alreadi servic rad pbm envisionrx
manag gave littl inform potenti win explain know
well view given exist relationship potenti gain signific
procur save join wbad good chanc win client
esrx contract fine despit upcom chang control renew esrx
five year contract explain hope ci-esrx merger
ultim win new busi ci pbm run optum current suppli op
accord discuss despit chang control manag explain
without go specif contract esrx fine esrx recent addit
wbad buy group encourag abc current contract compani
sound solid despit upcom merger
pillpack custom awar competit manag confirm
pillpack custom busi huge continu serv pillpack
follow purchas contract renew pillpack prior
acquisit outsid normal sale touch compani dialogu
ask investor manag explain awar competit
know must compet keep custom manag also explain though pillpack
deal expect close near year-end like take compani ramp
deal could make sens appear focus extract commerci
synergi manag field question vertic merger role distributor
play last stand-alone member suppli chain manag explain see
benefit join compani like explain much
overlap includ board seat high integr given work
partnership describ best deal ever done compani
continu explor way work close howev manag describ
alway work captur synergi mani synergi found
commerci without deal ponder deal explain must also think
dis-synergi competit ramif continu compet
aggress view deal could make sens long-term
manag admit could synergi howev believ deal happen
near-term
part bu tour moder discuss two medacorp pbm specialti
pharmaci specialist one kol formerli serv presid public specialti
pharmaci compani substanti experi run pbm kol built
sever pbm past decad current presid ceo privat
middle-market pbm group investor pepper specialist question
minut impact takeaway discuss follow
pbm sell season compar amount activ compar prior year
price far aggress competit case rate
declin one specialist said rate level never seen
accord specialist discern winner share donor
middle-market small pbm worri mega-d price power
leverag may abl bring market time middl
market pbm may competit advantag custom servic issu
way better express script deal make sens vault ci
high-end market deal allow realiz signific synergi
provid esrx stabl custom base
specialist believ cvs-aet new front door strategi work add
signific low-cost conveni channel market
migrat specialti drug spend medic benefit pharmaci benefit
improv total cost much
anthem ingeniorx remain build stage could realiz signific
save switch old contract esrx
healthcar distribut perspect estim would result least
save consist antm guidanc
shift drug medicar part part seen neutral posit event
suppli chain within part much aggress manag drug
spend howev specialist indic move part part
discuss year may never happen
specialist kept indic believ unlik rebat would simpli go
away indic price control would way cap rise drug
price chang rebat would unlik affect wacc instead elimin
rebat may simpli shift member
specialist highlight believ drug price increas ultim come
back probabl trend rang year
year overal increas annual
pillpack noth new alreadi exist market specialist agre
expens form distribut difficult amazon aggress sell
solut directli manag care plan
narrow network less popular past narrow network still
offer discount tend team sens
tend exclud slightli frequent
regard diplomat dplo op specialist mention havent seen
dplo market compet pbm deal lot work still need done
claim platform howev busi grow
transpar pass-through deal tend high-cost tradit spread
sell season highli competit consolid led larger contract
pbm compet aggress volum
industri consolid led pbm compet volum notic rate
compress kol panelist describ far pbm sell season
activ past year level competit notic higher one
specialist said price level never seen esrx recent guid retent
rate high rel previou year suspect express script
price aggress mainli want ensur deal
close report high retent rate head close odd deal
gain sharehold support increas believ aggress rate squeez express
script pbm margin compani consolid difficult discern
margin compress specialist also highlight pbm compet
aggress volum given continu payer consolid pbm also consolid
scale money chase larger volum consolid custom result
pbm tradit enjoy competit margin compet price
kol describ rate compress rel recent year view
high
winner emerg though competit increas kol seen clear
winner emerg yet specialist seem impress esrx appar success
enough market least partli off-set upcom loss busi
yet seen pbm face signific drop-off earn kol describ
one want larg share donor given greater consolid volum may mean
pbm may reduc price aggress near end sell season
report net new win year well net new win
report last year esrx increas retent rate guidanc
core claim expect increas y/i estim express script
price aggress result higher retent lower net new win
pbm market nervou follow vertic merger interest hear kol
explain mani market concern nervou follow vertic merger
sens nervous pervad marketplac payer worri
servic issu past merger activ led servic interrupt sound like pbm
concern competit ramif merger merg firm
pledg firewal place worri payer would effect open
book competit understand appreci view note
unh/optum run success integr model sever year continu work
independ compet payer believ diplomat dplo may benefit
market disrupt occur like occur futur howev
expect esrx face signific share loss price power typic far-
surpass middl market segment
vertic merger view favor kol necessarili compet payer
synergi effici improv creat compel valu kol panel
appear view vertic merger favor overal believ save much
total pharmaceut spend possibl result synergi effici
improv kol explain tradit handl pharmaci spend within
medic benefit archaic believ manag medic pharmaci
benefit togeth plan realiz signific effici improv shift drug
administ medic benefit pharmaci benefit rebat captur increas
allow use pbm tool includ pre-author step therapi quantiti limit etc
togeth provid better discount better point reimburs specialist
indic abil captur rebat drug current manag medic benefit
could gener save accord kol increas trend
recent year captur rebat drug tradit manag medic benefit like
hemophilia view may easier combin ci-esrx cvs-aet entiti
captur rebat addit drug therapi given market alreadi begun chang
aggreg effect rebat captur effici explain allow reduct
drug spend seem substanti view direct consist
ci-esrx deal mutual benefici one kol view way better esrx
kol also believ deal benefici esrx merger express script
gain captiv custom base signific posit follow loss allow
pbm bolster live drive increment increas market power
competit posit one kol explain believ acquisit allow ci vault
higher end market typic featur long-term contract attract margin
profil abil manag pharmaci benefit ci also abl expand
market includ self-fund market also featur longer sale cycl year
agreement averag
posit surpris hear kol indic evicor asset actual
perform well specialist indic solut effect manag
pharmaceut spend medic benefit typic receiv well health plan
commun comment contrast opinion heard differ pbm
specialist earlier year evicor may contribut express script improv retent
rate overal claim growth outlook
new front door work accord kol encourag hear confid
kol aim creat new front door healthcar work easi access
point larg retail network combin growth virtual care cite two larg
driver like success accord kol strategi provid live aet
platform much cheaper point access afford mani benefit
expect ci-esx merger mainli effici manag medic
pharmaci benefit gain captiv base live abl drive greater effici
addit bonu volum gain like occur retail store
specialist indic preval narrow network declin somewhat
view presenc restrict narrow network steadi may
aggress past regard retail reimburs rate suspect
rel larg share gain within medicar plan last year sent signal walgreen
market will match price fact price leader order retain
gain retail volum sinc trade blow back forth possibl
go forward may less aggress retail reimburs rate narrow
restrict network past
groundswel desir avoid larg insurance-own pbm may posit dplo
though kol view vertic merger favor caution
risk disrupt deal kol note seen increas
unwilling payer work pbm affili own compet insur
describ larg groundswel want go big box commentari seem
suggest mid-to small size payer may elect work smaller region pbm oper
mid-market note kol current work with/for mid-
market pbm may benefit trend view like bode well diplomat
pharmaci dplo indic number rfp opportun work
doubl rel last year believ in-sel opportun signific
pbm specialti servic
small pbm competit advantag lie servic transpar given groundswel
desir avoid larg pbm amid consolid kol explain small pbm
achiev competit advantag high servic level increas transpar accord
kol smaller payer want know money go flow want
higher level attent receiv big pbm manag vast custom
portfolio look flexibl area point differenti small
pbm exploit gain competit advantag word one kol time
larg disadvantag take comment grain salt
individu work middle-market pbm howev also like truth
comment given sharp y/i declin net new pbm win
dplo make push rare seen market improv on-going
dplo pivot pbm make sens pbm capabl still figur one
kol panel abl discuss diplomat due conflict express
believ dplo pivot becom pbm make sens point briova catamaran
accredo explain model alreadi proven effici
gain manag everyth one roof dplo strong specialti asset
recent acquir pbm function still figur pbm acquir describ
uniqu top notch also describ interest part play
dplo claim engin categor archaic dplo mail offer
pbm capabl label good enough commentari appear
glow note kol directli compet dplo market may temper
optimist comment howev comment consist channel check indic
dplo pbm capabl refin compani hire addit pbm expertis
bolster new offer remain confid dplo uniqu posit market
dplo make push one kol panel run mid-market pbm explain
rare see dplo market despit target mani client explain
know tri make play believ dplo need refin approach
win new busi view compani still tri figur go-to-market approach
point recent hire compani made hire peopl experi catamaran
optum kol explain specialti high point year ago suggest
dplo may reli heavili specialti henc recent hire addit pbm
personnel bolster pbm market strategi
dplo larger amount rebat captur due smaller contract june dplo face
signific weak follow file show pbm captur larger percentag
rebat esrx link estim dplo ebitda
retain rebat rebat come medicar medicaid kol
explain dplo fact reliant rebat current larger pbm
larg contract result admin fee exist
extent dplo current captur data fee kol said surpris see dplo
captur larger percent rebat larger competit dplo may current face
larger exposur rebat continu believ possibl dplo would seek
re-negoti client manufactur ensur econom deal chang
materi event regulatori chang continu believ risk pose
potenti rebat chang limit
move part part may neutral posit suppli chain
preval physician go direct manufactur may mean shift would posit
suppli chain surpris hear kol believ shift medicar part
part could benefici suppli chain howev skeptic chang would
actual occur point fact remain talk point year accord
kol mani physician go direct manufactur sever therapeut area tradit
administ part benefit result shift part would essenti forc
purchas back pharma suppli chain character neutral
posit pbm wholesal
chang rebat unlik affect price inflat pbm fee area
consist channel check kol explain chang rebat like lead
pbm shift compens fee absenc rebat point sale po
rebat would shrink pbm margin would like made larger administr
data fee stay whole result kol believ chang rebat structur
noth affect actual price econom suppli chain view way
affect meaning chang price pursu cost control remov rebat noth
wholesal acquisit cost wac upon price deriv pharma describ
kol big winner given role price setter remov rebat without price
control could lead manufactur profit accord kol
view rebat go away would lead slower rate growth list price sinc rebat
exist believ manufactur incent increas list price fairli rapid rate
need give lot rebat back channel give back didnt occur
rate list price growth wouldnt need high view assum
washington elect offici care win vote could greater effort
send rebat back patient point care way trump administr could
declar victori american peopl without disrupt entir system like outcom
howev would plan would simpli increas premium
price increas like resum rang annual twice year
earn wholesal disclos saw fewer price increas juli normal
typic brand drug manufactur take price increas januari juli howev
januari tradit common impact time price increas
wholesal caution seen mute fewer price increas normal juli
given increas scrutini kol corrobor comment explain believ
heighten scrutini led caution brand manufactur take price increas
wont put presid trump war path result appear
moder brand price inflat curv expect kol describ imagin mani
manufactur take mid-singl digit price increas stay price increas
threshold avoid scrutini may last throughout presid trump term
leav thing may becom interest indic increas twice
year like scenario
narrow network longer hot topic still deliv save narrow
network hot topic past year kol describ narrow network
push aggress today past possibl view
retail price pressur may abat result view may suggest pharmaci
retail reimburs rate reach somewhat floor given strong competit
past year kol describ remain activ tri secur narrow
network posit usual must supplement make /wmt network
combin reportedli aggress rate although narrow network
less popular still lead save one kol explain mean
pharmaci walk away almost margin view commentari posit
may mean hyper-aggress retail war temper
past
antm departur esrx could yield save surpris hear
kol describ decis leav esrx could result save
spent year esrx kol describ stale pbm contract like
rate probabl base nextrx purchas price led great margin
esrx like highli uncompetit rate bring pbm oper in-hous
kol explain better abl control list retain
profit switch achiev potenti save figur
save robust reportedli still build stage ingeniorx kol
seem believ work continu build
oper reli process claim pharmaci network
assum drug spend flow express script platform
improv overal cost would result save figur sound high
us view reason especi given fact esrx paid
nextrx pbm result above-market rate year assum
price go back market mean chang price signific
amazon-berkshire-jpm coalit sound promis kol worksit clinic
around decad accord kol work well correctli set howev
tend work best captiv employe base sever thousand employe work
similar offic space rather spread-out remot telecommut arrang
coalit abl creat effect employe benefit manag program kol
esrx total enu portion erat improv rate compani doucument leerink partner exposur mm healthcar distribut
suggest could look purchas region state-level insur plan gain addit
experi scale view amazon-berkshire-jpm coalit sound interest
like take year see tangibl result
pillpack acquisit seen step market current offer uniqu cost
effect note previous link pillpack offer uniqu one kol current
use similar servic medicar live manag pbm explain servic
expens like scalabl cost much tradit mail-ord
estim may cost much said kol believ acquisit
may make sens amazon state licens technolog help
speed entranc market howev caution amazon want becom
a-z pharmaci need acquir claim process servic interestingli kol
explain pillpack win manag care contract could like clear
insur hurdl could win addit contract howev technolog pillpack use
expens think less like abl win signific number
direct manag care plan deal well on-line pharmaci remain potenti growth area
although success previou attempt mani year ago addit
pharmaci amazon prime offer whole food store make sens agre
numer avenu amazon take expand footprint pharmaci continu
believ expans remain slow measur given complex market
amazon tradit market entranc strategi detail prior note speak
meet underscor shift valu underway
slow
addit meet kol panel also visit univers health servic
op encourag discuss quickli pivot valu base care risk
consist recent note recap value-bas care popul health puls call
link manag describ valu risk futur adopt far
slow somewhat neg surpris hear seemingli slow
rate adopt also medicar advantag busi grow seem indic
overal risk level within rel low
adopt risk shift valu earli inning end market
encourag meet hear discern trend shift valu
base care risk assumpt howev describ effici
low-cost provid less pressur assum risk end market result
assumpt risk describ far along sound like manag care
compani press chang encourag manag believ
shift valu trend believ slow adopt consist commentari
recent puls call describ slow steadi shift market assum
made acquisit becom better posit shift valu anticip
shift valu base care better oper aco bundl payment model
acquir insur underwrit provid manag explain
littl experi need oper success valu driven world chose
purchas expertis covet use acquisit creat relationship
aco creat medicar advantag product manag explain acquisit
gave great tool use go forward amid continu shift valu base care
insur care qualiti mainli focus rate though may result
effici low-cost provid manag describ insur alway
focus assumpt risk qualiti outcom describ big driver though
qualiti kicker come discuss howev explain though qualiti
focu earli stage talk insur alway go back pure rate
interest qualiti kicker find odd health plan arent aggress
push risk provid typic want implement per diem medacorp
check indic plan save signific dollar least total cost
shift risk member howev deal difficult implement complic
creat administ provid enter risk deal plan respons
provid provid claim data member give away proprietari
shift valu base care complic meet eye perhap interest
comment meet manag shift fee servic valu
base care much complic mani peopl assum manag describ
order take risk would need provid access medic loss data howev
insur may retic open book seem unlik mani insur would
want expos data view may headwind short term
on-going migrat valu base care believ market continu shift
unsustain cost trend matter time insur forc find way
make meaning shift risk
relationship ok client across acut care facil
util cern ehr implement ehr begin
implement cfo describ relationship ok explain
outsourc vendor frustrat also explain
major bump challeng believ relationship gone well gener
commentari glow endors encourag
process ad addit solut relationship behavior
health hospit compani use legaci siemen product yet found larg
viabl behavior product work
one pharmaceut distributor estim compani
captur pharmaceut distribut market term revenu
primari differenti distributor compani
focu specialti drug firm relationship estim
compani revenu deriv amerisourcebergen specialti group half
total revenu come oncology-rel busi come
drug compani non-specialti drug servic believ compani concentr
oncology-rel drug posit mani larg pend launch market
compani seem intens focu keep cost lean drive oper
margin expans watch measur everi basi point oper margin expans
quarterwhich view posit furthermor manag tend return signific
portion compani free cash flow back sharehold via common stock repurchas
dividend final abc relationship walgreen signific posit view sinc
walgreen own portion sinc walgreen use primari
distributor stand benefit wba growth market includ increment
volum result wba/ transact well increment volum
narrow network deal recent ink includ deal esrx/tricar optum
prime envis headwind exist includ competit sell-sid environ
on-going risk brand gener inflat rate presid trump potenti polici around
brand price unclear though believ ultim work industri despit
risk believ concern current reflect share price
increment revenu off-set mani headwind view given abc grow
market share seemingli decent brand inflat rate purchas power wbad growth
specialti market rate share outperform
share trade ep estim behind
ntm price-to-earnings histor averag rel ep trade
trade view deserv premium
group mainli abc relationship transact believ
new client win posit renew comp eas higher oper cost
allevi trend gener deflat stabil next month
expect share trade ep would put stock
competit intens amerisourcebergen compet two larg drug distributor
competit among intens could lead
either posit neg earn revis furthermor chain independ
consolid usual one distributor retain contract exampl walgreen
acquisit duan read acquisit long unfavor impact
result larg billion dollar piec busi often
chang hand occurr happen past may happen
futur competit could also lead price eros medco health solut part
esrx repres revenu pre-wag top ten custom repres
revenu pre-wag custom lost could materi advers
impact earn share price custom face financi hardship
abil collect receiv could becom challeng insolv
supplier could also result advers impact financi result stock
price economi impact earn result
brand-nam manufactur buy-sid contract fee-for-servic ff arrang
inflat deflat brand-nam drug usual less impact earn
rel contract ff howev sinc price receiv custom often
inflation-bas compon earn could unfavor impact addit economi
weak fewer peopl actual buy prescript drug due concern discretionari
spend lack health insur compani margin could come pressur
govern regul could advers impact compani
pharmaceut drug distribut industri highli regul state feder agenc
includ fda variou state board law pass
may pass futur intent increas safeti may like result
higher cost exampl radio frequenc identif devic may
prove costli track trace chain custodi technolog
also requir hold valid state-level licens meet variou secur oper
standard failur compli feder state local law could advers impact
compani earn
chang reimburs rate could impact earn effect januari
deficit reduct act dra chang feder upper limit
lowest publish price gener averag manufactur price
health reform set less medicaid
improv patient provid act mippa delay adopt
make public least delay implement set
becom public reimburs compani retail custom come
pressur could advers impact firm sell-sid margin addit
reimburs rate chang awp awp roll back could
unfavor impact earn declin asp reimburs
medicar certain specialti drug could also advers impact result
compani revenu growth rate certain drug use oncolog
come pressur expand warn product safeti label nation coverag
decis could advers impact compani revenu growth rate
reform drug reimburs chang canada could also advers impact
compani earn power
chang due health reform could advers impact compani product
servic highli complex pervas throughout entir healthcar system
extens array reimburs mechan player within industri
includ manag care medicar medicaid pbm supplier materi chang
entiti health reform could impact margin
consolid competitor supplier custom purchas group could
advers impact compani earn
litig alway risk compani subject signific number healthcar law
includ fals claim act whistl blower act law relat sale purchas
pharmaceut product exampl offer remuner provid use certain drug
may illeg case
oper risk compani make acquisit risk integr
could caus cost rise oper issu occur addit compani embark
cost save program well streamlin process could result oper
issu data lost compani new implement program face
challeng could advers impact compani earn share price
implement compani enterpris resourc plan erp system could also
advers impact earn oper
believ stand benefit brand gener convers pbm share gain growth
retail high growth rate specialti pharmaceut retail pharmaci
pbm believ differenti offer substanti buy power allow
compani price highli competit deliv high qualiti care uniqu cost
save model mani plan sponsor seek narrow network consid one
best market -- preval expect increas next
year estim alreadi one largest retail chain countri expect
addit growth come open new pharmaci acquisit
independ pharmaci smaller chain next sever year expect gener
drug launch advent biosimilar remain industri trend help drive
margin expans believ minuteclin benefit grow emphasi
popul health manag expect see increment benefit sell
season express script esrx optum continu streamlin oper
integr new custom win acquisit also posit propos cvs/aet
combin deal enabl live integr medic pharmaci
benefit aet live creat new sourc revenu earn
next month expect share trade ep
would put stock price target believ deserv
trade slight discount histor multipl given slowdown gener launch calendar
on-going challeng environ restrict narrow network howev
pick gross win pbm sell season reflect strength
core busi model furthermor lap lost rx headwind retail top-
line growth re-acceler believ well posit take advantag growth
gener specialti pharmaceut believ retail pbm valu proposit
mainten choic offer reson well market believ
continu win pbm share also help drive volum retail store
competit high chang retail pharmaci pbm market highli
competit industri consolid chang retail pbm landscap
acquisit medco express script merger health solut catalyst
health solut walgreen allianc boot combin
consolid market share among largest compani pbm may need price
aggress retain custom impact profit custom retent
macroeconom climat uncertain continu econom slowdown would bode
poorli client individu consum retail pharmaci product pbm plan
sponsor would suffer averag unemploy rate along averag level
consum spend purchas power would decreas prescript drug util weak
macroeconom outlook would also hurt profit pbm client possibl decreas
number cover live
organ govern entiti third-parti seek decreas prescript
drug cost seek increas substitut gener drug brand drug
normal benefici bottom line retail pharmaci downward pressur
reimburs rate pharmaci could start cut away margin consolid among
gener pharmaceut manufactur may squeez pharmaci would difficult
negoti reduc acquisit cost strong focu feder state govern
rein healthcar cost healthcar financ reimburs rate subject chang
variou polit econom interest exert influenc regulatori environ
failur retain/win new pbm contact pbm contract provid healthcar servic plan
member typic durat three year mean pbm client base
renew given year inher risk exist abil retain contract
renew also certain pbm client may tailor contract deviat typic term
may renegoti contract prior expir
medicar part regul risk particip medicar part prescript
drug program retail pharmaci realiz increas drug util compress
margin individu migrat higher margin plan one howev medicar
part busi could impact one sever factor includ chang drug cost
retire drug subsidi revis medicar program requir reduct fund failur
integr acquir medicar part busi failur win new contract
transact risk risk cvs/aet transact either wont close due
regulatori constraint integr deal may prove challeng
expect also risk invest commun sentiment transact
diplomat pharmaci inc diplomat oper fourth largest specialti pharmaci sp
 largest independ specialti pharmaci script believ specialti
pharmaci industri continu benefit sever key trend includ price inflat
new specialti drug launch expand indic exist drug potenti
acceler biosimilar specialti drug age popul competit strength
diplomat provid client addit believ diplomat uniqu posit
capit limit distribut specialti agreement substanti runway grow
market share specialti drug administ pharmaci medic benefit
also expect diplomat focu opportun within infus market
benefit ebitda margin expans new exist therapeut categori view
dplo recent pbm acquisit favor give dplo abil sell solut
beholden larger pbm price also encourag seem
pay closer attent dir fee challeng larger pbm brought
smaller specialti pharmaci dplo lap difficult hepat comp
earli believ dplo extract increment valu relationship
op believ smaller publicli trade pbm specialti
pharmaci typic sell larger enterpris think deal immin
believ current manag team open transact previou
team led founder phil hagerman given posit develop rate
share diplomat dplo outperform
diplomat share trade ev/ebitda includ increment
debt np ldi deal higher group averag believ
premium deserv given dplo growth profil potenti dplo acquir
larger enterpris good posit rapidli grow specialti market improv sentiment
next month expect dplo trade ev/ebitda
estim given stabil dir fee challeng hepat environ abil
dplo win new busi pbm well potenti takeout rate
competit high specialti pharmaci industri highli competit current
domin three player esrx mp op mp given rapid specialti market
growth spur new drug approv drug price inflat expect specialti
market remain attract new entrant market particip diplomat also sever
retail partnership pbm relationship custom develop acquir
specialti pharmaci may result custom loss diplomat
reimburs pressur could impact growth profit specialti drug spend
scrutin payor includ govern payor medicar medicaid legisl
bodi pressur mount limit reimburs runaway cost specialti drug
could put downward pressur price trend could advers impact diplomat growth
requir diplomat deliv addit valu ad servic payor
limit distribut agreement drug access emerg limit distribut
model specialti drug manufactur repres opportun diplomat also risk
compani longer abl secur limit distribut agreement lose access drug
specif manufactur diplomat current reli celg op signific portion
drug diplomat revenu came specialti drug
 integr rapid expans diplomat incorpor tuck-in acquisit
complement organ growth risk associ integr custom
technolog servic distribut diplomat excess facil capac posit
compani absorb volum increas success growth also reli hire new
employe given high-touch servic compon associ specialti pharmaci well
retain key employe manag member
litig risk diplomat handl sensit patient inform reli inform
technolog system could becom compromis secur breach could
result lawsuit exposur compani also provid limit compound servic could
expos compani certain litig risk
express script one largest pharmaci benefit manag pbm countri term
adjust script market believ pbm industri whole
benefit continu launch gener drug ii increas mail penetr iii
wave specialti drug insur compani self-insur employ group need
manag iv bio-similar estim gener drug dispens mail-ord
facil profit brand drug dispens non-own retail store
accord feder trade commiss ftc acquisit nextrx close
decemb esrx enter agreement wellpoint
perform pbm function member howev esrx face loss
largest client though larg built investor expect compani acquir
medco health solut april solidifi esrx posit largest pbm esrx
strong cash flow gener success integr acquisit onto singl
platform specialti drug come market believ employ group look
way control cost especi face recessionari pressur mani
theme benefit esrx past sever year mail penetr rate start
stagnat gener launch slow loss creat signific earn
challeng share esrx ralli ci transact expect anoth bidder
emerg believ stock fairli valu result rate share esrx market
esrx share current trade adjust ep estim
histor averag next month expect share
trade deal price price target
ep view high expect transact close
use slightli higher averag multipl pt given pend ci transact
encourag specialti growth comment around re-invest back
platform believ servic level improv although believ esrx
price aggress retain custom believ esrx better posit head
given servic improv see opportun win increment share
although stagnat mail penetr rate slowdown gener launch repres threat
key pillar esrx busi model view given run-up share price
deal still highli competit market rate esrx share market perform
complianc extens healthcar law regul place govern pbm
behavior state feder level mani law regul pertain fraud
abus privaci consum protect plan design restrict drug price medicar
medicaid reimburs drug import insur regul
signific custom concentr esrx depend relationship retail
pharmaci dispens prescript member compani lose materi amount
contract abil dispens medic member could impair potenti
result loss busi given esrx largest pbm term
adjust prescript think unlik retail chain would termin contract
compani loss contract creat signific earn headwind
pbm market competit pbm industri highli competit account come
renew put bid variou competitor includ like bid
aggress offer servic appear modestli differ esrx contract
typic last three year retent rate usual high level
competit allow client demand price reduct and/or larger share rebat
healthcar reform pbm risk legal process surround healthcar reform
believ transpar languag materi impact
pbm could prove risk busi client may seek higher share rebat
wholesal may tri negoti favor term
ci/esrx transact doj regul block ci/esrx transact could
signific downsid risk stock
good sold
revenu
revenu
revenu
incom statement model fiscal year end decemb mm
pharmaci retail
good sold
revenu
revenu
earn alloc particip secur
net loss attribut non-control interest
adjust incom continu oper
adjust one-tim item
adj incom cont op ex amort
adjust dilut ep ex amort
incom statement model fiscal year end decemb mm
net incom continu oper
net loss attribut non-control interest
prefer dividend net incom tax benefit
net incom attibut caremark
cog net revenu
oper expens net revenu
depreci amort
 total
incom statement model fiscal year end decemb mm
cog net revenu
oper expens net revenu
depreci amort
pharmaci total revenu
third parti pharmaci revenu
depreci amort
combin revenu
depreci amort
incom statement model fiscal year end decemb mm
sale
sale
sale
sale
chang fair valu redeem common
termin exist stock redempt
less net incom loss attrib nci
net incom attrib diplomat
alloc pref sharehold
gaap net incom alloc common
alloc pref sharehold
pro-forma net incom common
chang conting consider
impair non-consolid entiti
merger acquisit relat expens
less tax impact adjust
incom statement model fiscal year end decemb mm
incom statement model fiscal year end decemb mm
chang fair valu redeem common
termin exist stock redempt
equiti loss non-consol entiti
incom statement model fiscal year end septemb mm
good sold
distribut sell administr
total revenu
total revenu
impair intang
amort intang
total revenu
total revenu
weight average number share
employe sever litig
